<DOC>
	<DOCNO>NCT01463072</DOCNO>
	<brief_summary>This phase II trial study side effect paclitaxel albumin-stabilized nanoparticle formulation treat old patient breast cancer spread start nearby tissue lymph node ( locally advance ) place body ( metastatic ) . Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell stop dividing , stop spreading .</brief_summary>
	<brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation Treating Older Patients With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate tolerability ( grade 2-5 toxicity , neuropathy grade 2 high , need dose reduction , delay ) weekly nab-paclitaxel ( paclitaxel albumin-stabilized nanoparticle formulation ) old adult locally advance metastatic breast cancer . SECONDARY OBJECTIVES : I . To evaluate efficacy ( response time progression ) weekly nab-paclitaxel older adult locally advance metastatic breast cancer use stratification factor base patient age ( least 5 patient age 75 year old 15 patient age 65-70 year ) . II . To explore predictor need dose reduction , dose delay , grade 2-5 toxicity neuropathy grade 2 high base cancer-specific geriatric assessment . OUTLINE : Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously ( IV ) 30 minute day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Locally advanced metastatic breast cancer Any estrogen receptor ( ER ) , progesterone receptor ( PR ) , human epidermal growth factor receptor 2 ( Her2neu ) status long patient receive nabpaclitaxel alone First second line chemotherapy treatment metastatic disease Karnofsky performance scale ( KPS ) &gt; = 70 % Resolution grade &gt; = 2 toxicity prior therapy ( alopecia ) Peripheral neuropathy = &lt; grade 1 Absolute neutrophil count &gt; = 1,500/mm^3 Platelets &gt; = 100,000 cells/mm^3 Hemoglobin ( Hb ) &gt; = 9.0 g/dl Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x institutional upper limit normal Alkaline phosphatase = &lt; 2.5 x upper limit normal unless bone metastasis present absence liver metastases Bilirubin = &lt; 1.5 mg/dl Creatinine clearance ( calculated 24 hour ) &gt; = 30 ml/min Ability understand willingness sign write informed consent document Patients may receive investigational agent Untreated central nervous system ( CNS ) metastases symptomatic CNS metastasis require escalate dos corticosteroid Known history allergic reaction paclitaxel Presence serious uncontrolled infection Receipt taxane adjuvant therapy metastatic disease last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>